Please login to the form below

BI

This page shows the latest BI news and features for those working in and with pharma, biotech and healthcare.

Gilead drug reduces HIV viral reservoir, says researcher

After starting ART, the patients also received bi-weekly doses of either vesatolimod or placebo as an add-on therapy, and then came off therapy while they were monitored for a

Latest news

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Boehringer Ingelheim took a different tack with its Alzheimer’s candidate BI 409306, which targeted PDE9, but that drug also failed mid-stage testing and was unable to show any improvement
Boehringer bolsters NASH pipeline with Enleofen link-up

That has built on NASH-focused deals dating back several years including a 2015 alliance with Pharmaxis for AOC3 inhibitor BI 1467335 – now discontinued – and a $201m agreement with gene-silencing
Novartis picks up inclisiran after completion of MedCo acquisition

Repatha and Praluent are dosed more frequently – either monthly or bi-monthly.
Novartis acquires The Medicines Company for $9.7bn following takeover rumours

Repatha and Praluent are dosed more frequently – either monthly or bi-monthly.
GSK preps filings for BCMA-targeting multiple myeloma drug

idecabtagene vicleucel) slated for approval next year, and other drugs including a bi-specific antibody from Amgen called AMG 420.

More from news
Approximately 4 fully matching, plus 94 partially matching documents found.

Latest Intelligence

The ‘Million Hour Challenge’

Since the initiative launched, AstraZeneca has seen two consecutive increases in the bi-annual employee engagement survey, with 69% of AstraZeneca employees agreeing that ‘Together, we are making progress in our
Is it time we stopped talking about adherence?

attractive and valuable bi-product.
Deal Watch September 2016

Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma. ... Under the agreement, Daiichi Sankyo will acquire a licence to Zymeworks' platforms to develop a bi-specific antibody
The human perspective

But you can deal with the other three factors. This is where Boehringer has a key strength because there is a very, very strong culture, which is built on our BI
Deal Watch April 2016

1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours.

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

Havas Lynx Group

AbbVie. ALK. Astellas. AstraZeneca. Bayer. Boehringer Ingelheim. BI. BMS. Celgene. Sanofi Genzyme.
CSL

CSL are a healthcare specialist business intelligence consultancy. We help companies utilise tools like Power BI &Tableau.
Visual Numbers Limited

Offering Pharma companies a range of cost-effective ad hoc, interim or ongoing BI services (including GP practice Rx reports) and data Consultancy.
New Leaf Technology Solutions Ltd

market in areas such as Incentive Compensation, KAM, Coaching, Collaboration platforms and BI sol.
EphMRA Annual Conference 2018

In this paper, Ursula and Angela will show how they worked together on an initiative which would challenge the BI team’s comfort levels and capabilities, but ultimately elevate customer insights

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....